

Chapter 38 References

Ablin J, Fitzcharles MA, Buskila D, *et al.* Treatment of fibromyalgia syndrome: recommendations of recent evidence-based interdisciplinary guidelines with special emphasis on complementary and alternative therapies. *Evid Based Complement Alternat Med* 2013a;2013:485272.

Ablin JN, Häuser W, Buskila D. Spa treatment (balneotherapy) for fibromyalgia—a qualitative-narrative review and a historical perspective. *Evid Based Complement Alternat Med* 2013b;2013:638050.

Adamowicz JL, Caikauskaitė I, Friedberg F. Defining recovery in chronic fatigue syndrome: a critical review. *Qual Life Res* 2014;23:2407–16.

Annemans L, Wessely S, Spaepen E, *et al.* Health economic consequences related to the diagnosis of fibromyalgia syndrome. *Arthritis Rheum* 2008;58:895–902.

Arnold LM, Crofford LJ, Martin SA, *et al.* The effect of anxiety and depression on improvements in pain in a randomized, controlled trial of pregabalin for treatment of fibromyalgia. *Pain Med* 2007;8:633–8.

Atzeni F, Cazzola M, Benucci M, *et al.* Chronic widespread pain in the spectrum of rheumatological diseases. *Best Pract Res Clin Rheumatol* 2011;25:165–71.

Bates DW, Buchwald D, Lee J, *et al.* A comparison of case definitions of chronic fatigue syndrome. *Clin Infect Dis* 1994;18:S11–15.

Berger A, Dukes E, Martin S, Edelsberg J, Oster G. Characteristics and healthcare costs of patients with fibromyalgia syndrome. *Int J Clin Pract* 2007;61:1498–508.

Bernardy K, Klose P, Busch AJ, *et al.* Cognitive behavioural therapies for fibromyalgia. *Cochrane Database Syst Rev* 2013;9:CD009796.

Branco JC, Saraiva F, Matucci Cerinic M, *et al.* Fibromyalgia syndrome: a European epidemiological survey. *Ann Rheum Dis* 2005;64:547.

Brown MM, Jason LA. Functioning in individuals with chronic fatigue syndrome: increased impairment with co-occurring multiple chemical sensitivity and fibromyalgia. *Dyn Med* 2007;6:9.

Buskila D, Atzeni F, Sarzi-Puttini P. Etiology of fibromyalgia: the possible role of infection and vaccination. *Autoimmune Rev* 2008;8:41–3.

Caro XJ, Winter EF. Evidence of abnormal epidermal nerve fiber density in fibromyalgia: clinical and immunologic implications. *Arthritis Rheumatol* 2014;66:1945–54.

Carville SF, Arendt-Nielsen S, Bliddal H, *et al.* EULAR evidence-based recommendations for the management of fibromyalgia syndrome. *Ann Rheum Dis* 2008;67:536–41.

Cassisi G, Ceccherelli F, Atzeni F, Sarzi-Puttini P. Complementary and alternative medicine in fibromyalgia: a practical clinical debate of agreements and contrasts. *Clin Exp Rheumatol* 2013;31:S134–52.

Castelli L, Tesio V, Colonna F, *et al.* Alexithymia and psychological distress in fibromyalgia: prevalence and relation with quality of life. *Clin Exp Rheumatol* 2012;30:70–7.

Cazzola M, Sarzi Puttini P, Stisi S, *et al.* Fibromyalgia syndrome: definition and diagnostic aspects. *Reumatismo* 2008;60:3–14.

Clauw DJ. Fibromyalgia: a clinical review. *JAMA* 2014;311:1547–55.

Cook DB, Lange G, Ciccone DS, *et al.* Functional imaging of pain in patients with primary fibromyalgia. *J Rheumatol* 2004;31:364–78.

Dailey DL, Keffala VJ, Sluka KA. Cognitive and physical fatigue tasks enhance pain, cognitive fatigue and physical fatigue in people with fibromyalgia. *Arthritis Care Res (Hoboken)* 2014. [Epub ahead of print]

Devanur LD, Kerr JR. Chronic fatigue syndrome. *J Clin Virol* 2006;37:139–50.

Don Goldenberg M, Michael Mayskiy M, Christopher Mossey M. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. *Arthritis Rheum* 1996;39:1852–9.

Froiep R. *On the therapeutic application of electro-magnetism in the treatment of rheumatic and paralytic affections*. Translated by RM Lawrance. London: Henry Renshaw, 1850.

*Giesecke T, Williams DA, Harris RE, *et al.* Subgrouping of fibromyalgia patients on the basis of pressure-pain thresholds and psychological factors. *Arthritis Rheum* 2003;48:2916–22.

Gilson SF, Cramer EP, DePoy E. Redefining abuse of women with disabilities: a paradox of limitation and expansion. *Affilia* 2001;16:220–35.

Goesling J, Clauw DJ, Hassett AL. Pain and depression: an integrative review of neurobiological and psychological factors. *Curr Psychiatry Rep* 2013;15:421.

Gowers WR. Lumbago: its lessons and analogues. *Br Med J* 1904;1:117–21.

*Gracely RH, Petzke F, Wolf JM, *et al.* Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. *Arthritis Rheum* 2002;46:1333–43.

Gupta A, Silman AJ, Ray D, *et al.* The role of psychosocial factors in predicting the onset of chronic widespread pain: results from a prospective population-based study. *Rheumatology (Oxford)* 2007;46:666–71.

Hadler NM, Ehrlich GE. Fibromyalgia and the conundrum of disability determination. *J Occup Environ Med* 2003;45:1030–33.

Harris RE, Clauw DJ, Scott DJ, *et al.* Decreased central mu-opioid receptor availability in fibromyalgia. *J Neurosci* 2007;27:10000–6.

Häuser W, Walitt B, Fitzcharles MA, Sommer C. Review of pharmacological therapies in fibromyalgia syndrome. *Arthritis Res Ther* 2014;16:201.

Häuser W, Wolfe F, Tölle T, Uçeyler N, Sommer C. The role of antidepressants in the management of fibromyalgia syndrome: a systematic review and meta-analysis. *CNS Drugs* 2012;26:297–307.

Hauser W, Bernardy K, Arnold B, *et al.* Efficacy of multicomponent treatment in fibromyalgia syndrome: a meta-analysis of randomized controlled clinical trials. *Arthritis Rheum* 2009;61:216–24.

Hauser W, Klose P, Langhorst J, *et al.* Efficacy of different types of aerobic exercise in fibromyalgia syndrome: a systematic review and meta-analysis of randomised controlled trials. *Arthritis Res Ther* 2010;12:R79.

Hausteiner-Wiehle C, Henningsen P. Irritable bowel syndrome: relations with functional, mental, and somatoform disorders. *World J Gastroenterol* 2014;20:6024–30.

Hench PK. Nonarticular rheumatism, 22nd rheumatism review: review of the American and English literature for the years 1973 and 1974. *Arthritis Rheum* 1976;19(Suppl):1081–9.

Holman A, Myers R. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. *Arthritis Rheum* 2005;52:2495–505.

*Hughes G, Martinez C, Myon E, *et al.* The impact of a diagnosis of fibromyalgia on health care resource use by primary care patients in the UK: an observational study based on clinical practice. *Arthritis Rheum* 2006;54:177–83.

Kellgren JH. Observations on referred pain arising from muscle. *Clin Sci* 1938;3:175–90.

Lautenbacher S, Rollman G. Possible deficiencies of pain modulation in fibromyalgia. *Clin J Pain* 1997;13:189–96.

Lewis T. Suggestions related to the study of somatic pain. *Br Med J* 1938;1:321–5.

Lowe JC, Garrison RL, Reichman AJ, *et al.* Triiodothyronine (T3) treatment of euthyroid fibromyalgia. A small-n replication of a double-blind placebo-controlled crossover study. *Clin Bull Myofascial Ther* 1997;2:77–88.

McLean SA, Williams DA, Clauw DJ. Fibromyalgia after motor vehicle collision: evidence and implications. *Traffic Inj Prev* 2005;6:97–104.

Mogil JS. Animal models of pain: progress and challenges. *Nat Rev Neurosci* 2009;10:283–94.

Moldofsky H, Scarisbrick P, England R, *et al.* Musculoskeletal symptoms and non-REM sleep disturbance in patients with “fibrositis syndrome” and healthy subjects. *Psychosom Med* 1975;37:341–51.

Mountz JM, Bradley LA, Modell JG, *et al.* Fibromyalgia in women: abnormalities of regional cerebral blood flow in the thalamus and the caudate nucleus are associated with low pain threshold levels. *Arthritis Rheum* 1995;38:926–38.

Neumann L, Buskila D. Epidemiology of fibromyalgia. *Curr Pain Headache Rep* 2003;7:362–8.

Nishishinya B, Urrútia G, Walitt B, *et al.* Amitriptyline in the treatment of fibromyalgia: a systematic review of its efficacy. *Rheumatology* 2008;47:1741–6.

Perrot S, Bouhassira D, Fermanian J. Cercle d'etude de la douleur en rhumatologie. Development and validation of the fibromyalgia rapid screening tool (FiRST). *Pain* 2010;150:250–6.

Perrot S, Vicaut E, Servant D, Ravaud P. Prevalence of fibromyalgia in France: a multi-step study research combining national screening and clinical confirmation: the DEFI study (determination of epidemiology of fibromyalgia). *BMC Musculoskelet Disord* 2011;12:224.

Phillips K, Claw DJ. Central pain mechanisms in the rheumatic diseases: future directions. *Arthritis Rheum* 2013;65:291–302.

Picavet HS, Hoeymans N. Health related quality of life in multiple musculoskeletal diseases: SF-36 and EQ-5D in the DMC3 study. *Ann Rheum Dis* 2004;63:723–9.

Rehm SE, Koroschetz J, Gockel U, *et al.* A cross-sectional survey of 3035 patients with fibromyalgia: subgroups of patients with typical comorbidities and sensory symptom profiles. *Rheumatology (Oxford)* 2010;49:1146–52.

Salaffi F, Sarzi-Puttini P, Girolimetti R, *et al.* Development and validation of the self-administered fibromyalgia assessment status: a disease-specific composite measure for evaluating treatment effect. *Arthritis Res Ther* 2009;11:R125.

Smythe HA, Moldofsky H. Two contributions to understanding of the “Fibrositis” syndrome. *Bull Rheum Dis* 1977;28:928–31.

Vergne Salle P, Dufauret-Lombard C, Bonnet C, *et al.* A randomised, double-blind, placebo-controlled trial of dolasetron, a 5-hydroxytryptamine 3 receptor antagonist, in patients with fibromyalgia. *Eur J Pain* 2011;15:509–14.

White KP, NielsonWR, Harth M, *et al.* Does the label “fibromyalgia” alter service utilization? A prospective, within-group comparison in a community cohort of adults with chronic widespread pain. *Arthritis Rheum* 2002;47:260–5.

White KP, Speechley M, Harth M, Ostbye T. The London fibromyalgia epidemiology study: the prevalence of fibromyalgia syndrome in London, Ontario. *J Rheumatol* 1999;26:1570–6.

*Wolfe F. Fibromyalgianess. *Arthritis Rheum* 2009;61:715–16.

*Wolfe F. How to use the new American College of Rheumatology fibromyalgia diagnostic criteria [letter]. *Arthritis Care Res (Hoboken)* 2011;63:1073–4.

*Wolfe F, Anderson J, Harkness D, *et al.* Health status and disease severity in fibromyalgia: results of a six-center longitudinal study. *Arthritis Rheum* 1997;40:1571–9.

Wolfe F, Clauw DJ, Fitzcharles MA, *et al.* Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR preliminary diagnostic criteria for fibromyalgia. *J Rheumatol* 2011;38:1113–22.

*Wolfe F, Clauw DJ, Fitzcharles MA, *et al.* The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. *Arthritis Care Res* 2010;62:600–10.

*Wolfe F, Ross K, Anderson J, *et al.* The prevalence and characteristics of fibromyalgia in the general population. *Arthritis Rheum* 1995;38:19–28.

Wolfe F, Smythe HA, Yunus MB, *et al.* The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. *Arthritis Rheum* 1990;33:160–72.